Standout Papers
Citation Impact
Citing Papers
Preferential Generation of Follicular B Helper T Cells from Foxp3 + T Cells in Gut Peyer's Patches
2009 StandoutScienceNobel
Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
2012
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
2008 Standout
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
edgeR : a Bioconductor package for differential expression analysis of digital gene expression data
2009 Standout
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
On Differential Variability of Expression Ratios: Improving Statistical Inference about Gene Expression Changes from Microarray Data
2001
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
2014 Standout
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Biologic markers determine both the risk and the timing of recurrence in breast cancer
2011
Hallmarks of Cancer: The Next Generation
2011 Standout
The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer
2014
Letrozole in the extended adjuvant setting: MA.17
2007
The relationship between prognostic and predictive factors in the management of breast cancer
1998
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
2012
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
Pathways mediating VEGF-independent tumor angiogenesis
2009
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX
2011
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
2016
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20
2011
The biology and management of non-small cell lung cancer
2018 StandoutNature
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Primary Care for Survivors of Breast Cancer
2000
Lung Cancer
2008 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
2009 StandoutNobel
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
2010
S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen- receptor-positive breast cancer
1998
Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases
2011
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Control of the Immune Response by Pro-Angiogenic Factors
2014
Imaging angiogenesis of genitourinary tumors
2010
Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
2012
Role of Pemetrexed in Sdvanced Non-Small-Cell Lung Cancer: Meta-Analysis of Randomized Controlled Trials, with Histology Subgroup Analysis
2012
Stepwise Selection in Small Data Sets A Simulation Study of Bias in Logistic Regression Analysis
1999
Follicular B helper T cells in antibody responses and autoimmunity
2005
Evolving synergistic combinations of targeted immunotherapies to combat cancer
2015
Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer
2006
Global cancer statistics
2011 Standout
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Measuring inconsistency in meta-analyses
2003 Standout
Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments
2004 Standout
Prediction of Node-Negative Breast Cancer Outcome by Histologic Grading and S-Phase Analysis by Flow Cytometry
2001
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
2015
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Effects of Estrogen Receptor Expression and Histopathology on Annual Hazard Rates of Death from Breast Cancer
2006
Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer
2008
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study
2002
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
2007 Standout
limma powers differential expression analyses for RNA-sequencing and microarray studies
2015 Standout
Annual Report to the Nation on the Status of Cancer, 1975–2005, Featuring Trends in Lung Cancer, Tobacco Use, and Tobacco Control
2008
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
1996 Standout
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
2017
Estimation of the survival function for Gray's piecewise‐constant time‐varying coefficients model
2002
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women
1991
Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence
2004
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
2012
Tumor Angiogenesis
2008 Standout
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Drug Resistance and the Solid Tumor Microenvironment
2007 Standout
Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney Disease
2011 Standout
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Establishment of NOD-Pdcd1-/-mice as an efficient animal model of type I diabetes
2005 StandoutNobel
Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models
2021
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
2011
American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients
2006 Standout
Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
2008
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
2000
Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer
2008
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
2009
Immune targeting in breast cancer.
2015
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
2008 StandoutNobel
Time independence of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patients.
2001
Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102
2005
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
2001
Markers of Response for the Antiangiogenic Agent Bevacizumab
2013
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Integration of Molecular Profiling into the Lung Cancer Clinic
2009
Evaluation of Treatment-Effect Heterogeneity Using Biomarkers Measured on a Continuous Scale: Subpopulation Treatment Effect Pattern Plot
2010
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
2003 StandoutNobel
Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer
2007
Systematic reviews of trials and other studies.
1998
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
2016
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
2001 StandoutNobel
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
2016
Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer
2003
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
2007 Standout
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Chemoendocrine Therapy for Premenopausal Women With Axillary Lymph Node–Positive, Steroid Hormone Receptor–Positive Breast Cancer: Results From INT 0101 (E5188)
2005
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase
2010 StandoutNobel
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
2012
Metastatic Behavior of Breast Cancer Subtypes
2010 Standout
Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy
2008
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
2002 StandoutNobel
Proportional hazards tests and diagnostics based on weighted residuals
1994 Standout
Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
2007
Circulating Tumor Cells in Patients with Breast Cancer Dormancy
2004
Tamoxifen After Adjuvant Chemotherapy for Premenopausal Women With Lymph Node-Positive Breast Cancer: International Breast Cancer Study Group Trial 13-93
2006
Works of Robert J. Gray being referenced
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
2014
Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study
2008
Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study.
1990
Adjuvant Therapy for Very Young Women With Breast Cancer: Need for Tailored Treatments
2001
Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study.
1998
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
2006 Standout
Accumulation of p53 Protein as a Possible Predictor of Response to Adjuvant Combination Chemotherapy With Cyclophosphamide, Methotrexate, Fluorouracil, and Prednisone for Breast Cancer
1995
Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial.
1992
Annual hazard rates of recurrence for breast cancer after primary therapy.
1996
Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.
1998
An Audit Strategy for Progression-Free Survival
2011
Flexible Methods for Analyzing Survival Data Using Splines, with Applications to Breast Cancer Prognosis
1992
A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC).
2010
A Proportional Hazards Model for the Subdistribution of a Competing Risk
1999
Spline-Based Tests in Survival Analysis
1994
Bayesian Models for Gene Expression With DNA Microarray Data
2002
Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System
2007
Flexible Methods for Analyzing Survival Data Using Splines, With Applications to Breast Cancer Prognosis
1992
Some Diagnostic Methods for Cox Regression Models Through Hazard Smoothing
1990
Computing an Exact Confidence Interval for the Common Odds Ratio in Several 2×2 Contingency Tables
1985
Tests for Variation over Groups in Survival Data
1995
A Bayesian Analysis of Institutional Effects in a Multicenter Cancer Clinical Trial
1994
Prognostic Utility of the 21-Gene Assay in Hormone Receptor–Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features
2008